OBJECTIVE: To evaluate the relationship between open-angle glaucoma (OAG) and mortality in a black population at 9-years' follow-up. DESIGN: Population-based cohort study of 4092 black participants (aged 40-84 years at baseline) in the Barbados Eye Studies. Open-angle glaucoma was defined by visual field defects and optic disc damage, based on standardized examinations and photograph gradings. Ocular hypertension was defined by an intraocular pressure greater than 21 mm Hg or treatment, without OAG damage. Mortality was ascertained from death certificates. Cox proportional hazards regression analyses determined associations with mortality. RESULTS: After 9 years, 764 (19%) participants were deceased. Mortality was unrelated to overall OAG at baseline (n = 300) after adjustment for confounders. However, cardiovascular mortality tended to increase in persons with previously diagnosed/treated OAG (n = 141; relative risk [RR], 1.38, P = .07) and was significantly higher with treatment involving timolol maleate (RR, 1.91, P = .04). Cardiovascular deaths also tended to increase in persons with ocular hypertension at baseline (n = 498; RR, 1.28, P = .06). CONCLUSIONS: In this black population, cardiovascular mortality tended to increase in persons with previously diagnosed/treated OAG and ocular hypertension. The excess mortality associated with timolol maleate treatment of OAG, also found in a white population, warrants further investigation.
OBJECTIVE: To evaluate the relationship between open-angle glaucoma (OAG) and mortality in a black population at 9-years' follow-up. DESIGN: Population-based cohort study of 4092 black participants (aged 40-84 years at baseline) in the Barbados Eye Studies. Open-angle glaucoma was defined by visual field defects and optic disc damage, based on standardized examinations and photograph gradings. Ocular hypertension was defined by an intraocular pressure greater than 21 mm Hg or treatment, without OAG damage. Mortality was ascertained from death certificates. Cox proportional hazards regression analyses determined associations with mortality. RESULTS: After 9 years, 764 (19%) participants were deceased. Mortality was unrelated to overall OAG at baseline (n = 300) after adjustment for confounders. However, cardiovascular mortality tended to increase in persons with previously diagnosed/treated OAG (n = 141; relative risk [RR], 1.38, P = .07) and was significantly higher with treatment involving timolol maleate (RR, 1.91, P = .04). Cardiovascular deaths also tended to increase in persons with ocular hypertension at baseline (n = 498; RR, 1.28, P = .06). CONCLUSIONS: In this black population, cardiovascular mortality tended to increase in persons with previously diagnosed/treated OAG and ocular hypertension. The excess mortality associated with timolol maleate treatment of OAG, also found in a white population, warrants further investigation.
Authors: Michael A Kass; Mae O Gordon; Feng Gao; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John K Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson Journal: Arch Ophthalmol Date: 2010-03
Authors: Joan M O'Brien; Rebecca J Salowe; Raymond Fertig; Julia Salinas; Maxwell Pistilli; Prithvi S Sankar; Eydie Miller-Ellis; Amanda Lehman; Windell H A Murphy; Melissa Homsher; Katelyn Gordon; Gui-Shuang Ying Journal: Am J Ophthalmol Date: 2018-03-17 Impact factor: 5.258
Authors: Dianna J Magliano; Stefan Söderberg; Paul Z Zimmet; Bendix Cartensen; Beverly Balkau; Vassen Pauvaday; Sudhir Kowlessur; Jaakko Tuomilehto; K George M M Alberti; Jonathan E Shaw Journal: Diabetes Care Date: 2010-06-08 Impact factor: 19.112
Authors: Claude Pinnock; Jennifer L Y Yip; Anthony P Khawaja; Robert Luben; Shabina Hayat; David C Broadway; Paul J Foster; Kay-Tee Khaw; Nick Wareham Journal: Ophthalmic Epidemiol Date: 2016-08-23 Impact factor: 1.648
Authors: Rebecca Salowe; Julia Salinas; Neil H Farbman; Aishat Mohammed; Joshua Z Warren; Allison Rhodes; Alexander Brucker; Meredith Regina; Eydie Miller-Ellis; Prithvi S Sankar; Amanda Lehman; Joan M O'Brien Journal: J Clin Exp Ophthalmol Date: 2015-07-31